Marksans Pharma Limited share price

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelati…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - GeneralNifty Microcap 250NSE: MARKSANSISIN INE750C01026

16 Oct 2026, 3:29 PM IST₹311.00▲ 3.15 (1.02%)

Market Cap₹ 14,093 Cr.
Current Price₹ 311.00
High / Low₹ 351 / 155
Stock P/E27.3
Book Value₹ 67
Dividend Yield0.29 %
ROCE17.5 %
ROE15.20 %
Face Value₹ 1.0

More figures (10)

EPS (TTM)₹ 11.41
Price / Book4.66
OPM17.5 %
Debt / Equity0.11
Sales growth (5Y)16.5 %
Profit growth (5Y)12.0 %
Promoter holding43.9 %
EV / EBITDA19.9
Beta1.15
All-time high₹ 359

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
MARKSANS	-1.72%	+12.95%	+72.61%	+72.50%	+74.61%	+41.34%	+35.13%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Marksans Pharma Limited is in the Drug Manufacturers - General industry (Healthcare), with a market value of ₹14,093 crore.
It trades at 27.3 times its last 12 months' earnings and 4.7 times book value.
Revenue grew 16.5% a year over the last 5 years, profit 12.0% a year.
Return on equity was 15.2% and return on capital employed 17.5% in the latest year.
Debt was 0.11 times shareholders' equity.
The share price is 11.4% below its 52-week high and up 74.6% over one year.
Promoters and insiders hold about 43.9%; institutions about 18.4%.

Pros

Sales have grown 16.5% a year over the last 5 years.
Latest quarter (Jun 2026): sales up 36% and profit up 174% from a year ago.
Healthy return on equity of 16.2% on average over the last 3 years.
Trades at 27.3 times earnings, below its 3-year median of 237.7.
Borrowings are moderate at 0.11 times shareholders' equity.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Marksans Pharma Limited

Employees: 1,685
Head office: Mumbai
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - General

Part ofNifty Microcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Marksans Pharma	311.00	27.3	14,093	0.29	159	173.89	841	35.61	17.5	15.2	4.66	17.5	0.11	43.87	2,951	16.5
2.	GlaxoSmithKline Pharmaceuticals	2,566.10	40.7	43,471	2.26	237	-9.77	938	-3.69	55.4	49.1	19.17	32.8	0.01	75.63	3,808	5.7
3.	Rubicon Research	1,508.60	86.9	24,973	0.10	85	133.91	534	49.20	23.6	19.1	19.32	20.6	0.24	69.15	1,731	36.6
4.	SMS Pharmaceuticals	450.50	40.1	4,219	0.09	21	2.04	207	5.57	13.7	14.3	5.37	15.1	0.46	74.88	887	19.3
5.	Sai Parenteral's	487.30	168.0	2,153	0.00	8	—	179	—	17.9	21.1	3.25	6.4	1.83	74.83	381	126.1
6.	CORONA Remedies	2,003.90	61.6	—	0.49	60	—	422	—	29.0	27.4	16.41	18.3	0.22	77.61	1,403	16.6
	Median: 6 Co.	997.95	51.1	14,093	0.20	72	67.98	478	20.59	20.8	20.1	10.89	17.9	0.23	74.86	1,567	18.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	500	531	586	560	591	642	682	71	620	720	754	856	841
YOY Sales Growth %	15.28%	17.38%	22.15%	15.23%	18.12%	20.84%	16.33%	-87.35%	4.97%	12.23%	10.64%	1,108.42%	35.61%
	398	417	453	450	462	506	543	58	520	576	594	661	628
Material Cost %	49%	48%	47%	48%	44%	40%	44%	46%	42%	43%	42%	46%	41%
Employee Cost %	14%	13%	13%	14%	14%	13%	13%	14%	16%	14%	15%	12%	14%
Other Expenses %	17%	18%	18%	18%	20%	25%	23%	23%	26%	23%	22%	19%	20%
Operating Profit	102	114	133	110	128	136	139	13	100	144	161	195	213
OPM %	20%	21%	23%	20%	22%	21%	20%	18%	16%	20%	21%	23%	25%
Other Income	10	19	5	17	15	11	28	2	6	22	20	35	25
Interest	2	2	3	5	3	3	3	0	6	6	6	6	7
Depreciation	14	18	22	21	20	20	21	2	23	27	24	24	25
Profit before tax	97	114	113	100	120	125	143	12	77	133	151	200	207
	27%	26%	26%	23%	26%	22%	27%	22%	24%	26%	25%	25%	23%
Current tax	25	30	28	30	30	36	38	2	20	36	40	58	52
Deferred tax	1	0	2	-8	1	-9	0	0	-1	-2	-3	-7	-5
	70	84	83	78	89	98	105	9	58	99	114	149	159
Minority share	2	0	-0	-2	0	1	1		-0	1	0	1	2
Profit to shareholders	69	84	83	73	89	97	105		58	98	113	148	157
YOY Profit Growth %	17.04%	39.47%	33.16%	-6.13%	26.45%	16.59%	26.64%	-88.31%	-34.65%	1.41%	8.21%	1,542.66%	173.89%
EPS in Rs	0.15	0.18	0.18	0.17	0.20	0.21	0.23	0.20	1.29	2.17	2.50	3.27	3.47
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	182	205	241	225	255	309	312	299	320	320	340	362	321
YOY Sales Growth %	14.38%	20.21%	39.72%	47.14%	39.82%	50.79%	29.21%	32.93%	25.62%	3.83%	8.93%	20.78%	0.45%
	155	167	199	191	213	256	252	249	250	248	264	256	239
Material Cost %	57%	56%	57%	54%	55%	54%	55%	55%	52%	52%	51%	48%	49%
Employee Cost %	9%	9%	8%	10%	9%	8%	8%	10%	9%	9%	10%	9%	10%
Other Expenses %	19%	17%	17%	21%	20%	22%	18%	19%	18%	17%	17%	13%	15%
Operating Profit	27	37	42	34	41	52	60	51	70	72	75	106	82
OPM %	15%	18%	17%	15%	16%	17%	19%	17%	22%	22%	22%	29%	26%
Other Income	33	16	1	12	8	31	23	8	2	58	16	27	17
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	5	8	8	7	7	7	7	8	8	8	9	9	9
Profit before tax	54	45	35	38	42	76	75	50	64	121	82	124	90
	19%	30%	27%	14%	24%	17%	26%	25%	24%	18%	26%	26%	24%
Current tax	8	12	9	9	10	13	18	12	15	21	21	30	21
Deferred tax	3	2	0	-3	-0	1	2	1	1	1	0	2	0
	44	31	25	33	32	63	55	38	48	100	61	92	69
YOY Profit Growth %	130.09%	-22.22%	-1.31%	85.26%	-27.55%	102.00%	119.33%	13.93%	50.10%	57.91%	9.82%	144.53%	43.66%
EPS in Rs	0.98	0.69	0.56	0.73	0.71	1.39	1.22	0.83	1.06	2.20	1.34	2.03	1.52
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	767	1,000	1,134	1,376	1,491	1,852	2,177	262	2,951	3,172
YOY Sales Growth %		30.36%	13.41%	21.33%	8.33%	24.23%	17.56%	-87.95%	1,025.09%
	722	868	942	1,037	1,232	1,513	1,719	209	2,350	2,458
Material Cost %	60%	50%	48%	43%	48%	50%	48%	44%	43%	43%
Employee Cost %	20%	16%	15%	14%	15%	13%	13%	13%	14%	14%
Other Expenses %	15%	21%	20%	18%	20%	19%	18%	23%	22%	21%
Operating Profit	45	132	192	340	259	339	459	53	601	714
OPM %	6%	13%	17%	25%	17%	18%	21%	20%	20%	23%
Other Income	7	5	0	7	42	59	50	7	83	102
Interest	7	10	9	8	8	9	11	1	24	25
Depreciation	30	23	27	36	45	52	74	8	99	100
Profit before tax	15	104	157	302	248	338	424	50	561	691
	24%	23%	23%	21%	25%	21%	26%	24%	25%	25%
Current tax	5	24	32	67	57	71	113	13	153
Deferred tax	-1	0	4	-3	4	1	-5	-1	-13
	11	80	121	239	187	265	315	38	420	521
Minority share		4					1		2	5
Profit to shareholders		76					343		418	517
YOY Profit Growth %		609.64%	50.12%	97.54%	-21.68%	42.02%	18.68%	-87.85%	997.86%
EPS in Rs	0.02	0.19	0.29	0.58	0.45	0.64	0.69	0.84	9.22	11.41
Dividend Payout %						4%	7%		9%

Compounded Sales Growth

5 Years:: 16%
3 Years:: 17%
TTM:: 57%

Compounded Profit Growth

5 Years:: 12%
3 Years:: 17%
TTM:: 93%

Stock Price CAGR

5 Years:: 35%
3 Years:: 41%
1 Year:: 75%

Return on Equity

4 Years:: 16%
Last Year:: 15%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	295	424	433	600	658	655	853	1,174	1,341	1,343
YOY Sales Growth %		43.95%	2.18%	38.33%	9.80%	-0.47%	30.23%	37.63%	14.23%
	258	361	362	486	545	563	713	970	1,018	1,007
Material Cost %	57%	56%	56%	56%	57%	60%	56%	54%	51%	50%
Employee Cost %	16%	11%	11%	9%	9%	9%	9%	9%	9%	9%
Other Expenses %	15%	18%	16%	16%	16%	17%	18%	19%	16%	16%
Operating Profit	36	63	71	114	114	92	140	204	324	336
OPM %	12%	15%	16%	19%	17%	14%	16%	17%	24%	25%
Other Income	0	8	0	31	42	60	62	70	104	119
Interest	8	7	7	5	4	4	1	1	1	1
Depreciation	12	9	12	15	18	17	29	29	34	35
Profit before tax	17	56	53	124	135	132	172	243	392	418
	25%	22%	28%	21%	23%	22%	22%	23%	23%	23%
Current tax	4	12	12	28	30	30	37	52	86
Deferred tax	1	0	3	-2	1	-1	1	3	5
	12	44	38	98	104	103	134	188	301	322
YOY Profit Growth %		251.01%	-13.10%	159.56%	5.70%	-1.08%	30.03%	40.76%	59.71%
EPS in Rs	0.30	1.07	0.93	2.40	2.54	2.48	2.95	4.15	6.64	7.09
Dividend Payout %						10%	17%	14%	12%

Compounded Sales Growth

5 Years:: 17%
3 Years:: 27%
TTM:: 8%

Compounded Profit Growth

5 Years:: 25%
3 Years:: 43%
TTM:: 57%

Stock Price CAGR

5 Years:: 35%
3 Years:: 41%
1 Year:: 75%

Return on Equity

4 Years:: 16%
Last Year:: 15%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	45	45	45	45
Reserves	1,700	2,020	2,422	2,978
	123	244	322	343
Short term borrowings	42	29	23	30
	322	372	451	494
Trade payables	231	268	306	337
Minority interest	20	21	22	30
Current liabilities	341	390	477	527
Total Liabilities	2,190	2,681	3,240	3,861
	393	693	900	941
Gross block	629	986	1,251	1,405
Accumulated depreciation	236	293	351	464
Goodwill & intangibles	109	104	114	162
CWIP	13	18	13	15
	1,784	1,970	2,326	2,904
Inventories	485	618	846	972
Trade receivables	417	453	540	645
Cash & equivalents	382	403	496	634
Current assets	1,675	1,862	2,204	2,723
Total Assets	2,190	2,681	3,240	3,861

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	237	230	207	458
Profit for the year	266	314	381	418
Working capital changes	-111	-126	-241	-62
Direct taxes paid	-63	-122	-126	-140
	-259	-141	-49	-248
Fixed assets purchased	-54	-209	-173	-131
Fixed assets sold	0	1	1	1
Investments purchased	-190	-37		-296
Investments sold		73	89	151
	198	-69	-65	-71
Proceeds from borrowings	5
Repayment of borrowings		-12	-6
Interest paid	-6	-5	-2	-3
Dividends paid	-10	-23	-27	-36
Net Cash Flow	176	21	93	139
Free Cash Flow	184	22	34	328

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	15.3%	16.5%	16.8%	15.2%
ROCE	—	18.6%	19.0%	18.7%	17.5%
Operating margin	—	16.9%	17.8%	17.4%	17.5%
Net margin	—	14.4%	14.4%	14.6%	14.2%
Debt / equity	—	0.07	0.12	0.13	0.11
Current ratio	—	4.91	4.78	4.62	5.17
Debtor days	—	82	76	75	80
Inventory days	—	185	206	251	259
Days payable	—	88	89	91	90
Cash conversion cycle	—	179	193	235	249
Working capital days	—	263	247	241	272

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 43.87%
FIIs 19.06%
DIIs 5.54%
Public 31.53%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	43.85%	43.85%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%
	15.56%	15.57%	18.60%	21.31%	21.96%	22.20%	19.88%	16.92%	16.74%	16.76%	17.47%	19.06%
Foreign portfolio investors (Cat. I)	4.40%	4.40%	7.29%	10.05%	10.63%	10.24%	10.31%	7.53%	7.37%	7.32%	7.89%	9.35%
Foreign portfolio investors (Cat. II)	0.27%	0.29%	0.42%	0.38%	0.44%	1.07%	0.96%	0.77%	0.76%	0.82%	0.96%	1.09%
Foreign direct investment	10.88%	10.88%	10.88%	10.88%	10.88%	10.88%	8.62%	8.62%	8.62%	8.62%	8.62%	8.62%
	4.76%	5.17%	3.75%	4.10%	4.30%	4.56%	5.50%	5.28%	5.91%	6.57%	6.19%	5.54%
Mutual funds	3.82%	4.23%	2.82%	3.02%	3.15%	3.37%	3.55%	3.92%	4.41%	4.66%	4.36%	3.72%
Alternative investment funds	0.94%	0.94%	0.93%	1.08%	1.15%	1.18%	1.95%	1.36%	1.50%	1.91%	1.83%	1.82%
	35.83%	35.40%	33.78%	30.71%	29.87%	29.37%	30.75%	33.93%	33.47%	32.79%	32.47%	31.53%
Retail (up to ₹2 lakh)	26.56%	26.42%	24.96%	22.97%	22.49%	21.98%	23.03%	25.99%	25.34%	24.59%	24.33%	23.42%
HNIs (above ₹2 lakh)	4.24%	4.49%	4.51%	3.79%	3.75%	3.80%	3.71%	3.54%	3.64%	3.74%	3.72%	3.63%
NRIs	1.67%	1.74%	1.58%	1.44%	1.39%	1.35%	1.33%	1.52%	1.53%	1.51%	1.53%	1.49%
Bodies corporate	2.07%	1.52%	1.50%	1.42%	1.25%	1.30%	1.67%	1.83%	1.92%	1.90%	1.79%	1.85%
IEPF	0.15%	0.15%	0.15%	0.15%	0.18%	0.18%	0.18%	0.18%	0.18%	0.19%	0.19%	0.19%
No. of Shareholders	2,37,377	2,54,699	2,35,500	2,48,845	2,59,813	2,57,273	2,56,221	2,65,788	2,55,153	2,46,279	2,46,635	2,47,508

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Marksans Pharma

Holder (above 1%)	Stake
Uti-Healthcare FundMutual fund	1.66%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 3.72% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 20 Aug 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Marksans Pharma Limited

What is the share price of Marksans Pharma Limited today?

Marksans Pharma Limited (MARKSANS) last traded at ₹311.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Marksans Pharma Limited?

About ₹14,093 crore at the latest price.

What is the P/E ratio of Marksans Pharma Limited?

About 27.3 times its earnings over the last 12 months.

Is Marksans Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Marksans Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Marksans Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Marksans Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Marksans Pharma

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Marksans Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next